NCI-H441 Xenograft Model Service for NSCLC

NCI-H441 represents one of the few well-characterized preclinical systems derived from papillary lung adenocarcinoma, carrying a KRAS G12V oncogenic driver alongside homozygous TP53 disruption—making it an indispensable asset for interrogating RAS pathway dependencies in a histologically distinct NSCLC context. Alfa Cytology deploys this model through a fully traceable workflow: authenticated cell banking, pathogen-free animal sourcing, and integrated molecular analytics—delivering datasets that withstand the scrutiny of peer review and regulatory review alike.

Overview of NCI-H441 Xenograft Model for NSCLC

Papillary adenocarcinoma constitutes a recognized histological pattern within lung adenocarcinoma, distinguished by fibrovascular cores lined by malignant glandular epithelium and a propensity for aerogenous spread along alveolar walls. The NCI-H441 line was established in 1982 by A.F. Gazdar and colleagues from the pericardial effusion of a 62-year-old male patient, preserving both the papillary architecture and the bronchiolar differentiation program of the parent tumor. Ultrastructurally, NCI-H441 retains Clara cell (club cell) identity—evidenced by electron-dense cytoplasmic granules and multilamellar bodies—while simultaneously expressing surfactant protein A (SP-A) and surfactant protein B (SP-B), markers more typically associated with type II pneumocytes. This dual phenotype offers a unique window into the plasticity of lung epithelial malignancies. Genetically, the line harbors a KRAS G12V mutation (c.35G>T) in a heterozygous configuration, coupled with a homozygous TP53 missense alteration (p.Arg158Leu, c.473G>T), placing it in the KRAS-mutant/TP53-mutant molecular subgroup that accounts for a substantial fraction of smoking-associated lung adenocarcinomas.

Fig 1. Theasinensin A in combination with nimotuzumab induces tumor regression in the NCI-H441 xenograft tumor model. (Huang, Yanping, et al., 2023)

In the preclinical arena, NCI-H441 xenografts have proven responsive to a diverse array of mechanistic interventions. The model demonstrates marked sensitivity to LY2801653, a type II MET inhibitor, underscoring the role of MET signaling in KRAS-driven papillary tumors. More recently, the Pan-RAS inhibitor RMC-6236 elicited a 29% tumor regression in NCI-H441-bearing mice, validating the line as a predictive surrogate for RAS-directed therapies beyond allele-specific covalent inhibitors. The model has also served as a negative control for EGFR antibody therapy—necitumumab proved inactive, consistent with the absence of EGFR-activating mutations—while afatinib showed activity through an Elk-1-mediated CIP2A suppression mechanism unrelated to EGFR kinase inhibition. When propagated in immunodeficient hosts, NCI-H441 forms tumors that recapitulate the papillary morphology and immunohistochemical profile of the original biopsy, with a take rate amenable to statistically powered efficacy studies. These attributes collectively position NCI-H441 as a versatile and translationally relevant platform for evaluating novel agents in a molecularly annotated, histologically faithful lung cancer setting.

Cell Line Information: NCI-H441

NCI-H441 is a human papillary adenocarcinoma cell line extensively profiled across genomic, transcriptomic, ultrastructural, and functional dimensions. The table below distills the parameters most pertinent to preclinical xenograft design and interpretation:

Our Services

Alfa Cytology's NCI-H441 xenograft service is engineered for sponsors who demand both histological fidelity and molecular granularity. Every study begins with certified cell stocks, proceeds through IACUC-approved protocols in AAALAC-accredited vivaria, and concludes with a data package that integrates tumor kinetics, digital pathology, and mechanistic biomarker readouts—ready for regulatory filing or peer-reviewed publication.

Workflow of NCI-H441 Xenograft Model Construction

Constructing a robust NCI-H441 xenograft demands precision at every transition—from cryopreserved ampule to measurable tumor burden. The protocol below reflects the operational standards Alfa Cytology applies to ensure reproducible engraftment, consistent pharmacology, and audit-ready documentation:

1. Cell Line Revival and Expansion: Cryopreserved NCI-H441 vials are thawed and expanded in RPMI 1640 medium fortified with 10% FBS under standard incubation conditions (37°C, 5% CO₂). Each batch is screened for mycoplasma contamination, verified by STR profiling against the reference fingerprint, and assessed for viability before any in vivo use.
2. Recipient Mouse Qualification: Immunocompromised strains—athymic nude, NOD-SCID, or NSG mice aged 6–8 weeks—are procured from accredited vendors and quarantined for acclimatization. Health status is confirmed through body weight trending and clinical observation prior to tumor cell administration.
3. Tumor Cell Implantation: NCI-H441 cells harvested during logarithmic growth are washed, counted, and resuspended in sterile PBS or a 1:1 PBS/Matrigel matrix. For subcutaneous implantation, 2 × 10⁶ cells in 100–200 µL are delivered into the right flank. Orthotopic delivery into the thoracic cavity is available for studies requiring anatomically faithful tumor microenvironments.
4. Longitudinal Tumor Tracking: Palpable masses are measured twice weekly with digital calipers, and tumor burden is estimated via the ellipsoid formula (V = 0.5 × length × width²). Once tumors achieve 100–200 mm³, animals are stratified into cohorts balanced for starting volume, and in-life observations—including body weight and clinical scoring—continue throughout the dosing phase.
5. Therapeutic Dosing and Response Assessment: Investigational agents are administered according to the sponsor-defined schedule (route, dose level, and frequency). Tumor dimensions and animal weights are captured at predefined intervals to compute tumor growth inhibition (TGI), growth delay (TGD), and objective response metrics against vehicle-treated controls.
6. Terminal Characterization and Reporting: At study conclusion, tumors are excised, weighed, and subdivided for parallel analyses: formalin-fixed paraffin-embedded blocks for H&E and immunohistochemistry (Ki-67, cleaved caspase-3, KRAS pathway markers); snap-frozen tissue for PK/PD and biomarker quantification; and plasma sampling for exposure assessment. A statistically analyzed draft report is delivered for sponsor review.

Fig 2. NCI-H441 xenograft model construction workflow.

Case Study-NCI-H441 Xenograft Model Development

In a recent preclinical collaboration, NCI-H441 cells were engrafted subcutaneously into immunodeficient mice to benchmark a novel MET/AXL dual inhibitor against the standard-of-care reference compound. Tumors became palpable within 10–12 days post-implantation, and cohorts were randomized at a mean starting volume of 150 mm³. The test article was administered orally once daily for 28 days, with pharmacokinetic sampling on days 1 and 14 to confirm exposure levels. Tumor measurements captured twice weekly revealed dose-dependent growth suppression in the treatment arms, with the highest dose achieving tumor stasis relative to the vehicle control. At necropsy, excised tumors were analyzed by IHC for phospho-MET and phospho-AXL, showing concordant pathway downregulation in responders. Additional biomarker profiling revealed modulation of downstream KRAS effectors, supporting the hypothesized mechanism of action. Body weight trajectories remained stable across all cohorts, indicating an acceptable therapeutic index. The consolidated dataset—including tumor kinetics, biomarker modulation, and PK/PD correlations—was compiled into a comprehensive report that informed the sponsor's decision to advance the compound into extended toxicology studies.

Why Choose Alfa Cytology?

Selecting the right CRO partner can determine whether a preclinical program generates actionable insights or merely consumes budget and time. Alfa Cytology's NCI-H441 service is designed to maximize the former while minimizing the latter:

• Molecularly annotated model: NCI-H441 carries a well-defined KRAS G12V/TP53 p.Arg158Leu genotype, enabling mechanistic interpretation of drug responses and rational combination design rather than empirical screening alone.
• Histological fidelity: The line retains Clara cell/type II pneumocyte differentiation and papillary architecture in vivo, offering a tumor microenvironment that more closely mirrors human lung adenocarcinoma than undifferentiated models.
• Diverse pharmacological validation: NCI-H441 has demonstrated sensitivity to MET inhibitors, Pan-RAS inhibitors, and non-canonical EGFR pathway modulators—providing a versatile substrate for testing mechanistically distinct therapeutic hypotheses.
• Accelerated timelines: With a doubling time of approximately 58 hours under standard conditions, NCI-H441 tumors establish and reach target volume efficiently, compressing the interval from study start to data delivery.
• Integrated analytics: Beyond standard caliper-based efficacy, we offer multiplex IHC, Western blot, RNA-seq, and targeted proteomics to dissect on-target engagement, adaptive resistance, and combination rationale.
• Regulatory readiness: All studies are conducted under IACUC-approved protocols within AAALAC-accredited facilities, with GLP-like documentation suitable for IND-enabling packages and regulatory submissions.

Contact Us

Whether your program targets the RAS pathway directly, explores MET/AXL co-inhibition, or investigates synthetic lethal vulnerabilities in KRAS-mutant/TP53-mutant lung cancer, the NCI-H441 xenograft offers a predictive, well-characterized preclinical foundation. Contact us to arrange a scientific consultation, review our NCI-H441 qualification data, and receive a customized study proposal aligned with your discovery milestones and budget parameters.

For research use only. Not intended for any clinical use.